Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy

Abstract

Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy goal for both cardiologists and oncologists. The main strategy to prevent clinical cardiotoxicity is early detection and the initiation of prompt prophylactic therapy. EARLY DETECTION OF CARDIOTOXICITY Current approachPeriodic assessment for LVEF is the most widely used non-invasive method for detecting cardiotoxicity LVEF either via echocardiography or multigated acquisition scanning. Although several available guidelines exist none specify how often, by what means or how long cardiac function should be monitored during and after cancer treatment. The recommendations of these guidelines are not consistent and seem to be based on modest evidence. Though LVEF is a crude index of cardiac function, it is relatively insensitive in detecting anticancer drug-induced cardiotoxicity at an early stage. Usually there are compensatory mechanisms in place to ensure normal overall function in a patient despite an initial reduction in myocardial contractility. As a rule no considerable